| Stein, Eytan |
| Active, not recruiting | 2 | 95 | Europe, US | Tamibarotene, Venetoclax, Venclexta, Azacitidine, Vidaza | Syros Pharmaceuticals, Syros Pharmaceuticals, Inc. | Acute Myeloid Leukemia | 04/28 | 04/28 | | |
NCT05024994: A Study of E7820 in People With Bone Marrow (Myeloid) Cancers |
|
|
| Active, not recruiting | 2 | 12 | US | E7820 | Memorial Sloan Kettering Cancer Center, Eisai Inc. | Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia | 08/25 | 08/25 | | |
NCT06773208: A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML) |
|
|
| Recruiting | 2 | 30 | US | Azacitidine (AZC), Venetoclax | Memorial Sloan Kettering Cancer Center | Acute Myeloid Leukemia (AML) | 01/27 | 01/27 | | |
NCT05030441: Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1 |
|
|
| Recruiting | 2 | 20 | US | Ivosidenib, TIBSOVO | Washington University School of Medicine, Servier Hellas Pharmaceuticals Ltd., Gateway for Cancer Research | Clonal Cytopenia of Undetermined Significance | 01/30 | 01/30 | | |
| Terminated | 1/2 | 24 | Europe, US | Lanraplenib, LANRA, Gilteritinib, XOSPATA® | Kronos Bio, Kronos Bio, Inc. | Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | 04/24 | 04/24 | | |
| Recruiting | 1/2 | 2000 | US | Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Enasidenib, Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), GS-9973, ENTO, Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), TAK-924, MLN4924, Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21) | Beat AML, LLC | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | 12/26 | 12/26 | | |
|
NCT04243785: A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome |
|
|
| Recruiting | 1 | 80 | US | BTX-A51, Azacitidine | Edgewood Oncology Inc. | Acute Myeloid Leukemia, Myelodysplastic Syndrome | 03/26 | 03/27 | | |
NCT04402541: Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome |
|
|
| Completed | 1 | 55 | US, RoW | CB-5339, CB-5339 Tosylate | Cleave Therapeutics, Inc. | Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndromes | 07/23 | 07/23 | | |
NCT05144334: A Study of BTX-1188 in Subjects With Advanced Malignancies |
|
|
| Terminated | 1 | 8 | US | BTX-1188 | BioTheryX, Inc. | Advanced Solid Tumor, Non Hodgkin Lymphoma, Acute Myeloid Leukemia | 09/23 | 09/23 | | |
NCT06146257: A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes |
|
|
| Recruiting | 1 | 48 | US | GLB-001, GLB-C183-A-2 | GluBio Therapeutics Inc. | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 10/25 | 10/26 | | |
| Recruiting | 1 | 100 | US | REM-422 | Remix Therapeutics | Myelodysplastic Syndromes, Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory | 03/26 | 06/27 | | |
KT253-AL-101, NCT05775406: Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors |
|
|
| Completed | 1 | 52 | US | KT-253 | Kymera Therapeutics, Inc. | Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphomas, Advanced Solid Tumors | 12/24 | 12/24 | | |
NCT05756777: A Study of Gilteritinib in Combination with Ivosidenib or Enasidenib in People with Acute Myeloid Leukemia (AML) |
|
|
| Recruiting | 1 | 36 | US | Gilteritinib, Ivosidenib, Enasidenib | Memorial Sloan Kettering Cancer Center, Astellas Pharma US, Inc. | Acute Myeloid Leukemia (AML) | 02/25 | 02/25 | | |
| Recruiting | 1 | 144 | US | FHD-286, Low Dose Cytarabine, LDAC, Decitabine | Foghorn Therapeutics Inc. | Advanced Hematologic Malignancy, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Relapsed Myelodysplastic Syndromes, Refractory Myelodysplastic Syndromes, Relapsed Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia | 09/25 | 06/27 | | |
NCT05102370: A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance |
|
|
| Active, not recruiting | 1 | 4 | US | Enasidenib | Memorial Sloan Kettering Cancer Center | Clonal Cytopenia of Undetermined Significance, CCUS Clonal Cytopenia of Undetermined Significance | 10/25 | 10/25 | | |
| Recruiting | 1 | 50 | US | SGR-2921 | Schrödinger, Inc. | Acute Myeloid Leukemia, High-Risk and Very High-Risk Myelodysplastic Syndromes | 12/25 | 12/25 | | |
| Available | N/A | | US | Revumenib, SNDX-5613 | Syndax Pharmaceuticals | Relapsed/Refractory Acute Leukemia | | | | |
| Bolton, Kelly |
NCT06240754: Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial |
|
|
| Recruiting | 2 | 15 | US | Enasidenib | Washington University School of Medicine, Bristol-Myers Squibb, Damon Runyon Cancer Research Foundation | Clonal Cytopenia of Undetermined Significance, CCUS Clonal Cytopenia of Undetermined Significance | 09/26 | 10/26 | | |
NCT05030441: Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1 |
|
|
| Recruiting | 2 | 20 | US | Ivosidenib, TIBSOVO | Washington University School of Medicine, Servier Hellas Pharmaceuticals Ltd., Gateway for Cancer Research | Clonal Cytopenia of Undetermined Significance | 01/30 | 01/30 | | |
NCT05102370: A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance |
|
|
| Active, not recruiting | 1 | 4 | US | Enasidenib | Memorial Sloan Kettering Cancer Center | Clonal Cytopenia of Undetermined Significance, CCUS Clonal Cytopenia of Undetermined Significance | 10/25 | 10/25 | | |
NCT06008808: Ruxolitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation |
|
|
| Recruiting | 1 | 49 | US | Ruxolitinib, Jakafi | Washington University School of Medicine, Incyte Corporation | Graft Vs Host Disease, Graft-versus-host-disease, Graft Versus Host Disease | 09/26 | 12/26 | | |
NCT02604563: Aging, Geriatric Syndromes and Clonal Hematopoiesis |
|
|
| Recruiting | N/A | 2000 | US | Cognitive Assessment, Activities of Daily Living Questionnaire, Instrumental Activities of Daily Living, subscale of the OARS, Karnofsky Self-reported Performance Rating Scale, Number of Falls, Physical Health Section, subscale of the OARS, MOS Social Activity Survey, Unintentional Weight Loss, Peripheral Blood Draw, Buccal Swab, Heart Health and Smoking History from BRFSS questionnaire, Gait Speed, Grip Strength, Height and Weight measurements, Blood pressure measurement, Optional bone marrow biopsy, Blood draw for trauma measurements | Washington University School of Medicine, Edward P. Evans Foundation | Geriatrics, Aged, Geriatric Syndromes, Cardiovascular Diseases | 04/30 | 04/30 | | |
NCT05977036: BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer |
|
|
| Recruiting | N/A | 65 | US | DiviTum® TKa assay, CDK4/6 + Endocrine therapy | Washington University School of Medicine, Biovica | Metastatic Breast Cancer, Unresectable Breast Cancer | 09/34 | 09/34 | | |
